Amgenentech, Inc. has developed a new agent (Solvital) for the treatment of disease X. The table below summarizes the present values of cost and health outcomes associated with the use of Solvital in population Z with disease X over a 20 year period, compared to currently available treatment alternatives:

Treatment	Cost	QALYs
No Rx	10,000	5
Drug A	24,000	9
Drug B	42,000	11
Drug C	48,000	12
Sovital	528,000	16

Suppose you are an executive in a managed care organization charged with the responsibility of determining whether Solvital will be covered for the treatment of disease X in population Z within your health plan.

Complete the table below with treatments ordered from least to most costly to provide a complete incremental cost-effectiveness analysis for this problem, and answer the following questions: [Explain your answers]

Treatment	Cost	QALYs	Cost	QALYs	ICER
No Rx	10,000	5
Drug A	24,000	9
Drug B	42,000	11
Drug C	48,000	12
Sovital	528,000	16